1. Home
  2. NTIP vs MDCX Comparison

NTIP vs MDCX Comparison

Compare NTIP & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTIP
  • MDCX
  • Stock Information
  • Founded
  • NTIP 1990
  • MDCX 2008
  • Country
  • NTIP United States
  • MDCX United States
  • Employees
  • NTIP N/A
  • MDCX N/A
  • Industry
  • NTIP Multi-Sector Companies
  • MDCX
  • Sector
  • NTIP Miscellaneous
  • MDCX
  • Exchange
  • NTIP Nasdaq
  • MDCX Nasdaq
  • Market Cap
  • NTIP 32.0M
  • MDCX 36.2M
  • IPO Year
  • NTIP 1998
  • MDCX N/A
  • Fundamental
  • Price
  • NTIP N/A
  • MDCX $2.44
  • Analyst Decision
  • NTIP
  • MDCX Strong Buy
  • Analyst Count
  • NTIP 0
  • MDCX 2
  • Target Price
  • NTIP N/A
  • MDCX $23.50
  • AVG Volume (30 Days)
  • NTIP 39.0K
  • MDCX 410.3K
  • Earning Date
  • NTIP 10-23-2025
  • MDCX 11-22-2025
  • Dividend Yield
  • NTIP 6.49%
  • MDCX N/A
  • EPS Growth
  • NTIP N/A
  • MDCX N/A
  • EPS
  • NTIP N/A
  • MDCX N/A
  • Revenue
  • NTIP $150,000.00
  • MDCX N/A
  • Revenue This Year
  • NTIP N/A
  • MDCX N/A
  • Revenue Next Year
  • NTIP N/A
  • MDCX N/A
  • P/E Ratio
  • NTIP N/A
  • MDCX N/A
  • Revenue Growth
  • NTIP N/A
  • MDCX N/A
  • 52 Week Low
  • NTIP $1.16
  • MDCX $1.79
  • 52 Week High
  • NTIP $1.90
  • MDCX $8.94
  • Technical
  • Relative Strength Index (RSI)
  • NTIP N/A
  • MDCX 49.21
  • Support Level
  • NTIP N/A
  • MDCX $2.33
  • Resistance Level
  • NTIP N/A
  • MDCX $2.62
  • Average True Range (ATR)
  • NTIP 0.00
  • MDCX 0.23
  • MACD
  • NTIP 0.00
  • MDCX -0.02
  • Stochastic Oscillator
  • NTIP 0.00
  • MDCX 23.22

About NTIP Network-1 Technologies Inc.

Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.

About MDCX Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

Share on Social Networks: